menu
    • menu
    [{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Lipella Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Collaboration","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Urology","graph2":"Phase II","graph3":"Cook MyoSite","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cook MyoSite \/ Lipella Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Cook MyoSite \/ Lipella Pharmaceuticals"},{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"AMDC","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Cook MyoSite","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cook MyoSite \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cook MyoSite \/ Undisclosed"},{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"AMDC-USR","moa":"Undisclosed","graph1":"Urology","graph2":"Phase III","graph3":"Cook MyoSite","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cook MyoSite \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cook MyoSite \/ Undisclosed"},{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"AMDC-USR","moa":"Undisclosed","graph1":"Urology","graph2":"Phase III","graph3":"Cook MyoSite","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cook MyoSite \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cook MyoSite \/ Undisclosed"},{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Muscle Derived Cell","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Cook MyoSite","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cook MyoSite \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Cook MyoSite \/ Undisclosed"},{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Autologous Muscle-Derived Cell","moa":"Undisclosed","graph1":"Urology","graph2":"Phase I\/ Phase II","graph3":"Cook MyoSite","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cook MyoSite \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cook MyoSite \/ Undisclosed"},{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Iltamiocel","moa":"Unknown","graph1":"Urology","graph2":"Phase III","graph3":"Cook MyoSite","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cook MyoSite \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cook MyoSite \/ Undisclosed"},{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Iltamiocel","moa":"Unknown","graph1":"Urology","graph2":"Phase III","graph3":"Cook MyoSite","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cook MyoSite \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cook MyoSite \/ Undisclosed"},{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Iltamiocel","moa":"Unknown","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Cook MyoSite","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cook MyoSite \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cook MyoSite \/ Undisclosed"},{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Iltamiocel","moa":"Unknown","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Cook MyoSite","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cook MyoSite \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cook MyoSite \/ Undisclosed"},{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Veristat","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Partnership","leadProduct":"Iltamiocel","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Cook MyoSite","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cook MyoSite \/ Cook MyoSite","highestDevelopmentStatusID":"10","companyTruncated":"Cook MyoSite \/ Cook MyoSite"},{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Peter Belafsky, MD","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Autologous Muscle Derived Stem Cell","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Cook MyoSite","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cook MyoSite \/ Peter Belafsky, MD","highestDevelopmentStatusID":"6","companyTruncated":"Cook MyoSite \/ Peter Belafsky, MD"}]

    Find Clinical Drug Pipeline Developments & Deals by Cook MyoSite

    Menu

    Cook MyoSite

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cook MyoSite

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Cook MyoSite

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iltamiocel

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Recipient : Veristat

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Cook MyoSite and Veristat Partner in Phase III, Adaptive Clinical Study of iltamiocel

                            Details : The partnership aims to support the DigniFI Study, a two-stage, randomized, controlled Phase 3 comparing the safety and efficacy of iltamiocel with placebo.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            September 16, 2025

                            Lead Product(s) : Iltamiocel

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Recipient : Veristat

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cook MyoSite

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Cook MyoSite

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Urology

                            Study Phase : Phase II

                            Sponsor : Lipella Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite

                            Details : The collaboration aims to facilitate Chemistry, Manufacturing, and Control documentation for Lipella's drug candidate LP-10 (liposomal tacrolimus), aimed at treating hemorrhagic cystitis. LP-10 has been granted Orphan Drug Designation by the FDA.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            April 17, 2023

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Urology

                            Highest Development Status : Phase II

                            Sponsor : Lipella Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cook MyoSite

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Cook MyoSite

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iltamiocel

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

                            Details : Iltamiocel is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Fecal Incontinence.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            March 20, 2023

                            Lead Product(s) : Iltamiocel

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cook MyoSite

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Cook MyoSite

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous Muscle Derived Cell

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Expanded Access Program for Autologous Muscle Derived Cells (AMDCs)

                            Details : Autologous Muscle Derived Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 10, 2020

                            Lead Product(s) : Autologous Muscle Derived Cell

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cook MyoSite

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Cook MyoSite

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMDC-USR

                            Therapeutic Area : Urology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Japanese Bridging Study of Autologous Muscle Derived Cells Compared to Placebo for Female Urinary Sphincter Re...

                            Details : AMDC-USR is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Incontinence, Stress.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            June 25, 2019

                            Lead Product(s) : AMDC-USR

                            Therapeutic Area : Urology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cook MyoSite

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Cook MyoSite

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iltamiocel

                            Therapeutic Area : Urology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stres...

                            Details : AMDC-USR (Iltamiocel) is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Incontinence, Stress.

                            Product Name : AMDC-USR

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 07, 2017

                            Lead Product(s) : Iltamiocel

                            Therapeutic Area : Urology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cook MyoSite

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Cook MyoSite

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous Muscle Derived Stem Cell

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase I

                            Sponsor : Peter Belafsky, MD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia

                            Details : Autologous Muscle Derived Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Deglutition Disorders.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 20, 2016

                            Lead Product(s) : Autologous Muscle Derived Stem Cell

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase I

                            Sponsor : Peter Belafsky, MD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cook MyoSite

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Cook MyoSite

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous Muscle-Derived Cell

                            Therapeutic Area : Urology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery

                            Details : Autologous Muscle-Derived Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Urinary Incontinence.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            November 14, 2014

                            Lead Product(s) : Autologous Muscle-Derived Cell

                            Therapeutic Area : Urology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cook MyoSite

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Cook MyoSite

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iltamiocel

                            Therapeutic Area : Urology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Autologous Muscle Derived Cells for Female Urinary Sphincter Repair

                            Details : Iltamiocel is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Incontinence, Stress.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 08, 2013

                            Lead Product(s) : Iltamiocel

                            Therapeutic Area : Urology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Cook MyoSite

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Cook MyoSite

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iltamiocel

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Autologous Cell Therapy for Treatment of Fecal Incontinence

                            Details : Iltamiocel is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Fecal Incontinence.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 17, 2012

                            Lead Product(s) : Iltamiocel

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth